Clozapine (CLZ) represents an effective treatment for resistant schizophrenia. However, myocarditis, recently reported in about 66% of the psychiatric patients treated with CLZ, has raised concerns about its safety. β-blocking agents have shown to be helpful in the management of myocarditis.
View Article and Find Full Text PDF